AEON on NYSE
AEON Biopharma, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Selling, general and administrative | $12.2M | $13.6M |
| Research and development | $4.1M | $14.2M |
| Change in fair value of contingent consideration | -$3.5M | -$100.8M |
| Total operating costs and expenses | $12.8M | -$73.0M |
| (Loss) income from operations | -$12.8M | $73.0M |
| Change in fair value of convertible notes | -$22.9M | $3.3M |
| Change in fair value of warrants | $84.9M | -$14.7M |
| Loss on issuance of warrants | -$75.6M | |
| Loss on embedded forward purchase agreements | -$19.7M | |
| Loss on derivative liability | -$13.1M | |
| Other income, net | $290.0K | $95.0K |
| Total other loss, net | -$26.4M | -$31.0M |
| (Loss) income before taxes | -$39.2M | $42.0M |
| Income taxes | $0 | $0 |
| Net (loss) income | -$39.2M | $42.0M |
| Basic net (loss) income per share (in dollars per share) | -$3.95 | $77.74 |
| Diluted net (loss) income per share (in dollars per share) | -$3.95 | $72.93 |
| Weighted average shares of common stock outstanding used to compute basic net (loss) income per share | 9.9M shares | 540.4K shares |
| Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share | 9.9M shares | 575.9K shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.0M | $13.0K | |
| Prepaid expenses and other current assets | $392.0K | $1.6M | |
| Total current assets | $3.4M | $1.6M | |
| Property and equipment, net | $162.0K | $235.0K | |
| Operating lease right-of-use asset | $1.1M | $1.3M | |
| Other assets | $948.0K | $29.0K | |
| Total assets | $5.6M | $3.1M | |
| Accounts payable | $942.0K | $5.9M | |
| Accrued clinical trials expenses | $1.4M | $3.6M | |
| Accrued compensation | $2.9M | $1.1M | |
| Other accrued expenses | $1.7M | $3.6M | |
| Total current liabilities | $6.9M | $14.1M | |
| Convertible notes at fair value, including related party amount of $34,600 and $11,689, at December 31, 2025 and 2024, respectively | $34.6M | $11.7M | |
| Operating lease liability | $893.0K | $1.1M | |
| Derivative liability | $14.9M | ||
| Warrant liabilities | $3.3M | $1.2M | |
| Contingent consideration liability | $42.0K | $3.5M | |
| Total liabilities | $60.6M | $31.7M | |
| Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at December 31, 2025 and 2024, and 12,105,902 and 555,511 shares issued and outstanding at December 31, 2025 and 2024, respectively | $9.0K | $4.0K | |
| Additional paid-in capital | $415.8M | $403.0M | |
| Accumulated deficit | -$470.8M | -$431.6M | |
| Total stockholders' deficit | -$55.0M | -$28.6M | |
| Total liabilities and stockholders' deficit | $5.6M | $3.1M | |
| Common stock, par value | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 1.0B shares | 1.0B shares | 500.0M shares |
| Common stock, shares issued | 12.1M shares | 555.5K shares | |
| Common stock, shares outstanding | 12.1M shares | 555.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net (loss) income | -$39.2M | $42.0M |
| Depreciation | $78.0K | $97.0K |
| Stock-based compensation expense | $5.3M | $6.2M |
| Non-cash issuance of common stock | $250.0K | $384.0K |
| Loss on issuance of warrants | $75.6M | |
| Change in fair value of convertible notes | $22.9M | -$3.3M |
| Change in fair value of warrants | -$84.9M | $14.7M |
| Change in fair value of embedded forward purchase agreements | $19.7M | |
| Loss on derivative liability | $13.1M | |
| Change in fair value of contingent consideration | -$3.5M | -$100.8M |
| Prepaid expenses and other current assets | $1.2M | -$513.0K |
| Accounts payable | -$5.0M | $2.5M |
| Accrued expenses and other liabilities | -$2.2M | -$1.4M |
| Other assets and liabilities | -$952.0K | $120.0K |
| Net cash used in operating activities | -$17.3M | -$20.3M |
| Purchases of property and equipment | -$4.0K | |
| Net cash used in investing activities | -$4.0K | |
| Proceeds from issuance of convertible notes | $15.0M | |
| Net cash provided by financing activities | $20.3M | $15.1M |
| Net decrease in cash | $3.0M | -$5.1M |
| Settlement of liability with common shares | $235.0K | |
| Cashless warrant exercises | $7.0M |
Former names
- Priveterra Acquisition Corp.Dec 23, 2020 to Jul 24, 20232
Recent filings
- Oct 13, 2026PRE 14A
- Sep 30, 20268-K
- Aug 21, 20263
- Aug 21, 20264
- Aug 21, 2026SCHEDULE 13G
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Aug 3, 20268-K
- Jul 23, 20268-K
- Jul 21, 2026SCHEDULE 13G
- Jul 15, 2026424B4
- Jul 15, 20268-K
- Jul 13, 2026S-1MEF
- Jul 13, 2026EFFECT
- Jul 9, 2026S-1/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9